Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis.

NCT06570291 is registered in ClinicalTrials.gov with Wuxi Cellular Biopharmaceutical Group Ltd. as lead sponsor.

NCT NCT06570291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06570291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis.
Lead sponsor
Wuxi Cellular Biopharmaceutical Group Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
February 28, 2025
Completion date
December 31, 2028
Enrollment
520 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis